Cancer immunotherapies, such as anti-CTLA4 and anti-PD1 therapies, improved the prognosis and OS in metastatic and advanced melanoma (Ladányi, 2015; Davis et al., 2019). The gene discussed is CTLA4; the disease is cancer.